Akero Therapeutics Inc (AKRO)
21.60
-0.19
(-0.87%)
USD |
NASDAQ |
Apr 17, 16:00
21.61
+0.01
(+0.05%)
After-Hours: 20:00
Akero Therapeutics Cash from Operations (TTM): -145.37M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -145.37M |
September 30, 2023 | -122.25M |
June 30, 2023 | -97.15M |
March 31, 2023 | -94.27M |
December 31, 2022 | -92.52M |
September 30, 2022 | -93.70M |
June 30, 2022 | -83.69M |
March 31, 2022 | -84.21M |
December 31, 2021 | -79.68M |
September 30, 2021 | -76.38M |
June 30, 2021 | -75.28M |
Date | Value |
---|---|
March 31, 2021 | -77.83M |
December 31, 2020 | -70.80M |
September 30, 2020 | -59.06M |
June 30, 2020 | -58.76M |
March 31, 2020 | -41.50M |
December 31, 2019 | -35.63M |
September 30, 2019 | -26.05M |
June 30, 2019 | -14.80M |
March 31, 2019 | -9.731M |
December 31, 2018 | -4.625M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-145.37M
Minimum
Dec 2023
-14.80M
Maximum
Jun 2019
-75.21M
Average
-77.83M
Median
Mar 2021
Cash from Operations (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | -324.23M |
89bio Inc | -129.19M |
Viking Therapeutics Inc | -73.38M |
Eli Lilly and Co | 4.240B |
Ionis Pharmaceuticals Inc | -307.51M |